<p>The brain drug developer plans to slash R&D expenses by about 60% in the wake of the FDA surprisingly rejecting its rare disease drug Vyglxia.</p>
Knocked back by the FDA, Biohaven turns to major cost cuts
BioPharma Dive Oncology | | Jacob Bell
Topics: oncology